ATE420625T1 - Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt - Google Patents

Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt

Info

Publication number
ATE420625T1
ATE420625T1 AT06842710T AT06842710T ATE420625T1 AT E420625 T1 ATE420625 T1 AT E420625T1 AT 06842710 T AT06842710 T AT 06842710T AT 06842710 T AT06842710 T AT 06842710T AT E420625 T1 ATE420625 T1 AT E420625T1
Authority
AT
Austria
Prior art keywords
emulsion compositions
preservative effect
intravenous propofol
monoglyceryl ester
propofol emulsion
Prior art date
Application number
AT06842710T
Other languages
English (en)
Inventor
Gautam DAFTARY
Srikanth Pai
Girish Shanbhag
Sangeeta Rivankar
Original Assignee
Bharat Serums & Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd filed Critical Bharat Serums & Vaccines Ltd
Application granted granted Critical
Publication of ATE420625T1 publication Critical patent/ATE420625T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06842710T 2005-08-05 2006-08-04 Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt ATE420625T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN906MU2005 2005-08-05

Publications (1)

Publication Number Publication Date
ATE420625T1 true ATE420625T1 (de) 2009-01-15

Family

ID=38006301

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06842710T ATE420625T1 (de) 2005-08-05 2006-08-04 Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt

Country Status (16)

Country Link
US (1) US8759404B2 (de)
EP (1) EP1922060B1 (de)
JP (1) JP2009503059A (de)
KR (1) KR20080043793A (de)
CN (1) CN101304728A (de)
AT (1) ATE420625T1 (de)
AU (1) AU2006310113A1 (de)
BR (1) BRPI0614084A2 (de)
CA (1) CA2618026A1 (de)
DE (1) DE602006004887D1 (de)
EA (1) EA200800258A1 (de)
ES (1) ES2318802T3 (de)
IL (1) IL189310A0 (de)
MX (1) MX2008001746A (de)
WO (1) WO2007052288A2 (de)
ZA (1) ZA200801227B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030450A2 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
WO2008023384A1 (en) * 2006-08-24 2008-02-28 Bharat Serums & Vaccines Ltd. Propofol emulsion compositions for intravenous administration
BRPI0604377A (pt) * 2006-10-27 2008-06-24 Cristalia Prod Quimicos Farm microemulsão óleo/água de propofol estável e pronta-para-uso
JP2010163397A (ja) * 2009-01-16 2010-07-29 Japan Ecologia Co Ltd 抗菌性組成物
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de) 2010-11-11 2012-06-13 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
KR101910213B1 (ko) 2011-01-04 2018-12-19 노바리크 게엠베하 부분불소화된 알칸을 포함하는 수중유형 에멀젼
EP2714010B1 (de) 2011-05-25 2017-03-01 Novaliq GmbH Topische pharmazeutische zusammensetzung auf der basis von semifluorierten alkanen
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
KR20150008086A (ko) * 2012-04-20 2015-01-21 헨네핀 라이프 사이언스 미생물 감염증의 국소 치료용 조성물
WO2014033751A2 (en) * 2012-08-16 2014-03-06 Emcure Pharmaceuticals Limited Pharmaceutical composition of propofol
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
WO2017001549A1 (en) * 2015-07-01 2017-01-05 Fresenius Kabi Deutschland Gmbh Propofol emulsion for parenteral administration
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
ES2819005T3 (es) 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
EP3612228B1 (de) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Jodzusammensetzungen
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019123221A1 (en) * 2017-12-20 2019-06-27 Aurobindo Pharma Limited Pharmaceutical composition comprising clevidipine and process for preparation thereof
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3784246A1 (de) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmische zusammensetzungen mit tafluprost zur behandlung von glaukomen
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3923907B1 (de) 2019-02-13 2024-09-25 Novaliq GmbH Zusammensetzungen und verfahren zur behandlung von okularer neovaskularisation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067997A (en) * 1975-05-21 1978-01-10 Med-Chem Laboratories Synergistic microbecidal composition and method
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
CO4810371A1 (es) 1998-02-10 1999-06-30 Gensia Sicor Inc Composicion de propofol que contiene sulfito
US6028108A (en) 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140373A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6100302A (en) 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
SE0001865D0 (sv) * 2000-05-19 2000-05-19 Astrazeneca Ab Management of septic shock
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
AU6689601A (en) * 2000-06-16 2002-01-02 Rtp Pharma Inc Improved injectable dispersions of propofol
EP1337273A2 (de) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen enthaltend paclitaxel, dessen derivate und dessen pharmazeutisch denkbare saltze
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
MX2008001746A (es) 2008-04-07
US8759404B2 (en) 2014-06-24
ES2318802T3 (es) 2009-05-01
WO2007052288A2 (en) 2007-05-10
US20070249730A1 (en) 2007-10-25
ZA200801227B (en) 2008-12-31
CN101304728A (zh) 2008-11-12
BRPI0614084A2 (pt) 2011-03-09
DE602006004887D1 (de) 2009-03-05
EP1922060B1 (de) 2009-01-14
KR20080043793A (ko) 2008-05-19
AU2006310113A1 (en) 2007-05-10
EA200800258A1 (ru) 2008-06-30
WO2007052288A3 (en) 2007-08-30
JP2009503059A (ja) 2009-01-29
EP1922060A2 (de) 2008-05-21
IL189310A0 (en) 2008-06-05
CA2618026A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
DE602006004887D1 (de) Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
PH12017501328A1 (en) Self-emulsifying composition of ?-3 fatty acid
PL387009A1 (pl) Kompozycje zawierające wytworzone przez metatezę nienasycone estry polioli
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
UA89315C2 (en) Butylbenzene phthalein intravenous emulsion
BR0311764A (pt) Composição herbicida
AR039688A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
MX2010002930A (es) Formulaciones que comprenden una composicion anti-microbiana.
WO2007124465A3 (en) Stable emulsion formulations
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
AR062187A1 (es) Composicion insecticida
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
WO2004010941A3 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
AR056808A1 (es) Formulacion de aceite en agua de avermectinas
PL2048949T3 (pl) Środek konserwujący na bazie bezwodników kwasu karboksylowego
BRPI0516077A (pt) composições antimicrobianas compreendendo um agente natural selecionado de ácido gálico, eucalipotol, naringina, um composto de ácido jasmÈnico e qualquer combinação destes
AR055115A1 (es) Composiciones antitrnspirantes
EP1726632A4 (de) Abbauinhibitor
DE60232271D1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
JP2010163397A (ja) 抗菌性組成物
PT1171100E (pt) Composicao farmaceutica solubilizada para administracao parenteral
EA200700440A1 (ru) Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность
UA93529C2 (ru) Соли и смеси 9-оксоакридин-10-уксусной кислоты c 1-алкиламино-1-дезоксиполиолами

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties